Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Choosing ART for Pediatric Patients

Source: Key Decisions in HIV Care
Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for choosing ART for pediatric patients, including for HIV-exposed newborns and children and adolescents infected with HIV.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.

Listen as she gives perspectives on:

  • Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission
  • DHHS guideline–recommended ART regimens for children
  • The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents
  • Data for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescents
  • Key ART and management considerations for adolescents and young adults with HIV

Information on this Educational Activity

Faculty

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS

Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 21, 2022

Clinical Care Options (CCO) patient audio: Yvette Raphael provides her perspectives and advice as an individual living with HIV

person default Yvette Raphael Released: June 21, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings